Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00962845 · ClinicalTrials.gov registry record · Early Phase 1

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

A Early Phase 1 study of Melanoma (Skin), sponsored by Rutgers, The State University of New Jersey.

Completed
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT00962845: Completed Early Phase 1 study of Melanoma (Skin), sponsored by Rutgers, The State University of New Jersey.

NCT00962845 is a Early Phase 1 study of Melanoma (Skin) that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 20 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00962845, a Early Phase 1 study of Melanoma (Skin), has completed, sponsored by Rutgers, The State University of New Jersey.

COMPLETED
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers. PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage III or stage IV melanoma that can be removed by surgery.

Conditions Studied

Interventions

  • DRUG hydroxychloroquine

Study Locations (1)

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-09
Est. Completion 2013-05-30
Phase Early Phase 1

What the finished NCT00962845 record still lists

NCT00962845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 1 intervention - of which hydroxychloroquine is the first listed.

NCT00962845 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00962845 about?

NCT00962845 is a clinical study titled "Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery". RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers. PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage...

What is the current status of trial NCT00962845?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2010-09. Estimated completion is 2013-05-30.

What conditions does trial NCT00962845 study?

This clinical trial studies the following conditions: Melanoma (Skin).

What interventions are being tested in trial NCT00962845?

The interventions under investigation include: hydroxychloroquine (DRUG).

Who is sponsoring clinical trial NCT00962845?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00962845 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Melanoma (Skin)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00962845's enrollment target sits among peer trials

20 21st of 30 higher than 6 of 30 other Melanoma (Skin) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00962845, the US trial registry maintained by the National Library of Medicine. NCT00962845 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.